HPV16 E6 mutations and p53 codon72 polymorphism among women with cervical intraepithelial neoplasia 2 and 3 in China

Objective: To study the distribution of HPV16 E6 gene mutations and p53 codon72 polymorphism among women with HPV16+ cervical precancerous lesions and explore their relationship with the risk of cervical intraepithelial neoplasia (CIN) 2, 3. Materials and Methods: This study analyzed a total of 112 cases of exfoliated HPV16+ cervical cell specimens which were divided into group 1 (normal and CIN1, 55 cases) and group2 (CIN2, 3, 57 cases). Among the 112 specimens, 85 cases were successfully amplified for HPV E6 gene by PCR and the PCR products were sequenced directly. P53 codon72 region was also amplified from the 112 specimens and the PCR products were sequenced directly and compared with the standard sequence. Results: Among the 85 amplified HPV sequences, point mutations such as T178G, T350G, G132A, A442C, T310G, G94T, C551A, etc. were found, among which, T178G showed the highest rate (51.76%). The rate of HPV16 E6 mutation T178G in CIN2, 3 group was significantly higher than that in normal and CIN1 group, i.e., in the 112 amplified p53 codon72 sequences, the distribution of Pro/Pro genotype in normal, and CIN1 group was significantly different from that in CIN2, 3 groups, and the disease risk of Pro/Pro genotype was much higher than that of Arg/Arg and Arg/Pro genotypes. Conclusion: HPV16 E6 T178G mutation increases the disease risk of CIN2, 3. Meanwhile, compared with Arg/Arg and Arg/Pro genotypes, p53 codon72 Pro/Pro genotype more associated with the disease risk of CIN2, 3.

Cervical intraepithelial neoplasia; HPV16 E6; P53 codon72.

[1] Zhang J.G., Liu S.Z., Chen Q., Quan P.L., Lu J.B., Sun X.B., et al.: “Analysis of cervical cancer incidence and death of Chinese in 2009”. Chinese Tumor, 2013, 8, 612.

[2] Zhou Q.Y., Pan X.L., LI Xinmin, Zheng Xz, Yang Aq, Li HA, Yan Lh, et al.: “Mechanism of p53Arg72Pro polymorphism and HPV related cervical cancer”. Chinese Tumor, 2009, 2, 136.

[3] Cantarella G., Liniger M., Zuniga A., Schiller J.T., Billeter M., Naim H.Y., et al.: “Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma”. Vaccine, 2009, 27, 3385.

[4] Hariri S.., Steinau M., Rinas A., Gargano J.W., Ludema C., Unger E.R., et al.: “HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006”. PLoS One, 2012, 7, e34044.

[5] Li Jh, Wang Wj, Gao Wl, Guo Lf, Feng Lm, et al.: “Effects of HPV18 E6 siRNA on the proliferation and chemotherapy of cervical cancer cell sensitivity”. Basic Clin. Med., 2010, 30, 500.

[6] Derrien T., Johnson R., Bussotti G., Tanzer A., Djebali S., Tilgner H., Guernec G., et al.: “The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression”. Genome Res., 2012, 22, 1775.

[7] Ho L., Chan S.Y., Burk R.D., Das B.C., Fujinaga K., Icenogle J.P., et al.: “The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations”. J. Virol., 1993, 67, 6413.

[8] Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al.: “Role of p53 polymorphism in the development of human papillomavirus-associated cancer”. Nature, 1998, 93, 229

[9] Sun Z., Lu Z., Liu J., Wang G., Zhou W., Yang L., et al.: “Genetic variations of E6 and long control region of human papillomavirus type 16 from patients with cervical lesion in Liaoning”. China BMC Cancer, 2013, 13, 459.

[10] Wu Y., Chen Y., Li L., Yu G., He Y., Zhang Y., et al.: “Analysis of mutationsin the E6/E7 oncogenes and L1 gene of huma n papillomavirus 16 cervical cancer isolates from China”. J. Gen. Virol., 2006, 87, 1181.

[11] Cai H.B., Chen C.C., Ding X.H.: “Human papillomavirus type 16 E6 gene variations in Chinese population”. BMC Urol., 2005, 5, 15.

[12] Liu F., Ma Y.T., Yang Y.N., Xie X., Li X.M., Huang Y., et al.: “Medicine and clinical relationship based in Xinjiang Han and Uygur HPV16E6 gene variants and uterine cervix cancer and cervical lesions”. Basic Clin. Med., 2012, 3, 19.

[13] Jang M., Rhee J.E., Jang D.H., Kim S.S.: “Gene expression profiles are altered in human papillomavirus-16 E6 D25E-expressing cell lines”. J. Virol., 2011, 8, 453.

[14] Choi B.S., Kim S.S., Yun H., Jang D.H., Lee J.S.: “Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers”. J. Med. Virol., 2007, 79, 426.

[15] Wu Y., Chen Y., Li L., Yu G., He Y., Zhang Y., et al.: “Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China”. J. Gen. Virol., 2006, 87, 1181.

[16] Qmichou Z., Khyatti M., Berraho M., Ennaji M.M., Benbacer L., Nejjari C., et al.: “Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women”. BMC Infect Dis., 2013, 13, 378.

[17] Chen C.C.: “P53 gene codon72 polymorphism and HPV16 related cervical cancer in 2012”. Clin. Exp. Pathol., 2012, 19, 9.

[18] Min-min H., Ming-rong X., Ze-yi C., Kai-xuan Y., Zhi-lin S., et al.: “The relationship between P53 gene codon72 polymorphism and HPV-16, 18 E6 and cervical cancer”. Journal of Sichuan University (Medical Edition), 2006, 37, 404.

[19] Li J., Zheng Qy., et al.: “Meta analysis of P53 codon72 gene polymorphism and the risk for cervical cancer”. Journal of Xi'an Jiao Tong University (Medical Science Edition), 2005, 26, 384.

[20] Leiros G.J., Galliano S.R., Sember M.E., Kahn T., Schwarz E., Eiguchi K., et al.: “Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina”. BMC Urol., 2005, 5, 15.

[21] Wu Y., Chen Y., Li L., Yu G., Zhang Y., He Y., et al.: “Associations of high-risk HPV types and viral load with cervical cancer in China”. J. Clin. Virol., 2006, 35, 264.

[22] Sun F., Ha X.Q., Lv T.D., Xing C.P., Liu B., Cao X.Z., et al.: “Human papillomavirus 16E6 gene mutation in cervical carcinoma tissues”. Chinese Journal of Cancer, 2009, 28, 478.